Screener
Sutro Biopharma STRO Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Revenue | $14,523 | $17,399 |
| Operating expenses | ||
| Research and development | 36,553 | 51,597 |
| General and administrative | 7,584 | 13,273 |
| Restructuring and related costs | 42 | 21,043 |
| Total operating expenses | 44,179 | 85,913 |
| Loss from operations | (29,656) | (68,514) |
| Interest income | 1,635 | 3,189 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's total revenue?
- Sutro Biopharma (STRO) reported total revenue of $14.52M in Q1 2026.
- How has Sutro Biopharma's total revenue changed year-over-year?
- Sutro Biopharma's total revenue decreased by 16.5% year-over-year, from $17.4M to $14.52M.
- What is the long-term trend for Sutro Biopharma's total revenue?
- Over 4 years (2021 to 2025), Sutro Biopharma's total revenue has grown at a 13.4% compound annual growth rate (CAGR), from $61.88M to $102.48M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Sutro Biopharma's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude